{
    "nctId": "NCT06643884",
    "briefTitle": "Suprachoroidal Administration in Subjects With Choroidal Metastasis From Breast or Lung Primary Tumors",
    "officialTitle": "A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Bel-sar (AU-011) With Suprachoroidal Administration in Subjects With Choroidal Metastasis From Breast or Lung Primary Tumors",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Eye Cancer, Metastatic Breast Cancer, Lung Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "Change from baseline in choroidal tumor thickness on B-scan ultrasonography (B-scan) 4 weeks after completion of treatment.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Have a clinical diagnosis of Choroidal Metastasis, from a histopathologically or cytologically confirmed breast or lung primary tumor.\n* Have a single Choroidal Metastasis in only 1 eye, and no Choroidal Metastasis in the other eye (i.e., unilateral, unifocal Choroidal Metastasis).\n\nExclusion Criteria:\n\n* Active ocular infection or disease.\n* Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}